Lightchain Capital

Recent News

NextRNA-Logo-FullColor-400
September 26, 2024

NextRNA Therapeutics Expands Executive Team with Appointment of Jesse Smith, PhD as Chief Scientific Officer

READ MORE
C4-logo-wht
September 13, 2024

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

READ MORE
C4-logo-wht
September 10, 2024

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

READ MORE
NextRNA-Logo-FullColor-400
September 10, 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

READ MORE
C4-logo-wht
September 08, 2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

READ MORE
C4-logo-wht
September 03, 2024

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

READ MORE
C4-logo-wht
August 29, 2024

C4 Therapeutics to Participate in Upcoming September Investor Conferences

READ MORE
NextRNA-Logo-FullColor-400
August 28, 2024

Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in Oncology

READ MORE
NextRNA-Logo-FullColor-400
August 28, 2024

Bayer pens $547M biobucks pact with biotech pushing the boundaries of noncoding RNA

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2024 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group